GSK-Moderna deal shows value of patent access in crowded vaccine market
GSK and Moderna’s cross-license offers vaccine rivals a possible route through overlapping pipelines and uncertain patent litigation, lawyers told MLex. A pending US appeal could limit recovery against Moderna for government-supplied...To view the full article, register now.
Already a subscriber? Click here to view full article